NEW YORK, NY--(Marketwire - Nov 22, 2011) - Today, [ www.BrightonMarkets.com ] announced new reports highlighting Inhibitex, Inc. (NASDAQ: [ INHX ]) and Invesco Ltd. (NYSE: [ IVZ ]). Gain market insight with full analysis and research downloads available at [ www.BrightonMarkets.com/index.php?coa=INHX&cob=IVZ ].

Upcoming macro-economic 'tides of influence' are buoyed by crisis both home and abroad. Spanish and Italian yields continue to climb as efforts by the European Central Bank have stopped short of establishing sovereign bond guarantees for any one country. The result is historic yields and a grave concern for the solvency of interbank lending. Markets were drawn to concerns over domestic policy stalemates producing downgrade risks. Despite the situation, there continues to be unique value and opportunity found within careful discretion.

Brighton Markets is releasing new coverage on Inhibitex, Inc. for its current position within the healthcare industry. Inhibitex, Inc.is a biopharmaceutical company focused on the development of differentiated anti-infective products to prevent or treat serious infections. The full research report on Inhibitex, Inc. (NASDAQ: [ INHX ]) is available here: [ www.BrightonMarkets.com/index.php?coa=INHX ].

Brighton Markets has released research on Invesco Ltd. for its changing role within the financial industry. Invesco Ltd. (Invesco) is an independent global investment management company. Invesco provides a range of investment strategies and vehicles to its retail, institutional and high-net-worth clients globally. The full research report on Invesco Ltd. (NYSE: [ IVZ ]) is available here: [ www.BrightonMarkets.com/index.php?cob=IVZ ].

About Brighton Markets
Brighton Markets was founded on the guiding principle of providing highly relevant, meaningful, and actionable information direct to investors. Across the investment spectrum, Brighton Markets shines light on today's events.